Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "MANA"

3001 News Found

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY


Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India
News | August 12, 2025

Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease


Lupin partners with Sadoz to commercialise Ranibizumab biosimilar
News | August 12, 2025

Lupin partners with Sadoz to commercialise Ranibizumab biosimilar

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A


Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad
Biotech | August 11, 2025

Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad

Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance


Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP
Drug Approval | August 11, 2025

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP

Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle


Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
Drug Approval | August 11, 2025

Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India


Wockhardt reports Q1 FY26 loss at Rs. 108 Cr
News | August 10, 2025

Wockhardt reports Q1 FY26 loss at Rs. 108 Cr

Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a


Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
News | August 10, 2025

Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore


Akums reports Q1 FY26 PAT at Rs. 65 Cr
News | August 09, 2025

Akums reports Q1 FY26 PAT at Rs. 65 Cr

During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals